Short Interest in vTv Therapeutics Inc. (NASDAQ:VTVT) Decreases By 13.6%

vTv Therapeutics Inc. (NASDAQ:VTVT) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 24,100 shares, a decline of 13.6% from the February 13th total of 27,900 shares. Currently, 1.6% of the shares of the company are sold short. Based on an average daily volume of 13,300 shares, the days-to-cover ratio is currently 1.8 days.

Analyst Ratings Changes

Several analysts have weighed in on VTVT shares. Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They set a “buy” rating and a $35.00 target price for the company. StockNews.com initiated coverage on shares of vTv Therapeutics in a research report on Wednesday. They set a “sell” rating for the company.

vTv Therapeutics Trading Down 13.0 %

Shares of vTv Therapeutics stock opened at $18.26 on Thursday. The stock has a market capitalization of $58.25 million, a price-to-earnings ratio of -4.03 and a beta of 1.07. vTv Therapeutics has a twelve month low of $12.12 and a twelve month high of $30.99. The business’s 50 day simple moving average is $16.85 and its 200-day simple moving average is $15.42.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in shares of vTv Therapeutics during the fourth quarter worth about $25,000. Geode Capital Management LLC lifted its position in vTv Therapeutics by 12.9% in the 4th quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after purchasing an additional 1,327 shares during the last quarter. Finally, FMR LLC acquired a new position in vTv Therapeutics during the 3rd quarter valued at about $2,402,000. 17.51% of the stock is currently owned by institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.